Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$2.14 USD
-0.03 (-1.38%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $2.17 +0.03 (1.40%) 5:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APVO 2.14 -0.03(-1.38%)
Will APVO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APVO
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
APVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for APVO
Aptevo Therapeutics files to sell 8.25M shares of common stock for holders
Aptevo Therapeutics (APVO) Schedules Offering of 8.25 Million Shares
Aptevo Therapeutics files to sell 8.25M shares of common stock for holders
Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous
12 Health Care Stocks Moving In Friday's Intraday Session